The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blazar, B. R.
Right arrow Articles by Taylor, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blazar, B. R.
Right arrow Articles by Taylor, P. A.
The Journal of Immunology, 2000, 165: 4901-4909.
Copyright © 2000 by The American Association of Immunologists

Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions1

Bruce R. Blazar2,*, Christopher J. Lees*, Paul J. Martin{dagger}, Randolph J. Noelle{ddagger}, Byoung Kwon§, William Murphy and Patricia A. Taylor*

* University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, Minneapolis, MN 55455; {dagger} Division of Clinical Research, Fred Hutchinson Cancer Research Center Department of Medicine, Seattle, WA 98195; {ddagger} Department of Microbiology, Dartmouth Medical College, Hanover, NH 03756; § Department of Ophthalmology, Louisiana State University Medical Center, New Orleans, LA 70112; and Science Applications International-Frederick and the Laboratory of Leukocyte Biology, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702

Delayed lymphocyte infusions (DLIs) are used to treat relapse occurring post bone marrow transplantation (BMT) and to increase the donor chimerism in recipients receiving nonmyeloablative conditioning. As compared with donor lymphocytes given early post-BMT, DLIs are associated with a reduced risk of graft-vs-host disease (GVHD). The mechanism(s) responsible for such resistance have remained incompletely defined. We now have observed that host T cells present 3 wk after lethal total body irradiation, at the time of DLI, contribute to DLI-GVHD resistance. The infusion of donor splenocytes on day 0, a time when host bone marrow (BM)-derived T cells are absent, results in greater expansion than later post-BMT when host and donor BM-derived T cells coexist. Selective depletion of host T cells with anti-Thy1 allelic mAb increased the GVHD risk of DLI, indicating that a Thy1+ host T cell regulated DLI-GVHD lethality. The conditions by which host T cells are required for optimal DLI resistance were determined. Recipients unable to express CD28 or 4-1BB were as susceptible to DLI-GVHD as anti-Thy1 allelic mAb-treated recipients, indicating that CD28 and 4-1BB are critical to DLI-GVHD resistance. Recipients deficient in both perforin and Fas ligand but not individually were highly susceptible to DLI-GVHD. Recipients that cannot produce IFN-{gamma} were more susceptible to DLI-GVHD, whereas those deficient in IL-12 or p55 TNFRI were not. Collectively, these data indicate that host T cells, which are capable of generating antidonor CTL effector cells, are responsible for the impaired ability of DLI to induce GVHD. These same mechanisms may limit the efficacy of DLI in cancer therapy under some conditions.




This article has been cited by other articles:


Home page
BloodHome page
J. S. Miller and B. R. Blazar
Response: The role of G-CSF on the risk of graft-versus-host disease after donor lymphocyte infusions
Blood, May 15, 2008; 111(10): 5256 - 5257.
[Full Text] [PDF]


Home page
BloodHome page
S. Mielke, K. Rezvani, B. N. Savani, R. Nunes, A. S. M. Yong, J. Schindler, R. Kurlander, V. Ghetie, E. J. Read, S. R. Solomon, et al.
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease
Blood, September 1, 2007; 110(5): 1689 - 1697.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Durakovic, V. Radojcic, M. Skarica, K. B. Bezak, J. D. Powell, E. J. Fuchs, and L. Luznik
Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Blood, May 15, 2007; 109(10): 4564 - 4574.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Rezvani, S. Mielke, M. Ahmadzadeh, Y. Kilical, B. N. Savani, J. Zeilah, K. Keyvanfar, A. Montero, N. Hensel, R. Kurlander, et al.
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
Blood, August 15, 2006; 108(4): 1291 - 1297.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Fukushima, T. Yamaguchi, W. Ishida, K. Fukata, R. S. Mittler, H. Yagita, and H. Ueno
Engagement of 4-1BB Inhibits the Development of Experimental Allergic Conjunctivitis in Mice
J. Immunol., October 15, 2005; 175(8): 4897 - 4903.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. P. Rettig, J. K. Ritchey, J. L. Prior, J. S. Haug, D. Piwnica-Worms, and J. F. DiPersio
Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation
J. Immunol., September 15, 2004; 173(6): 3620 - 3630.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. E. Anderson, J. M. McNiff, C. Matte, I. Athanasiadis, W. D. Shlomchik, and M. J. Shlomchik
Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease
Blood, September 1, 2004; 104(5): 1565 - 1573.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. J. Young, L. S. Kay, M. J. Phillips, and L. Zhang
Antitumor Activity Mediated by Double-Negative T Cells
Cancer Res., November 15, 2003; 63(22): 8014 - 8021.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer
Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions
Blood, July 15, 2003; 102(2): 740 - 748.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Hummel, D. Wilms, M. Vitacolonna, and M. Zoller
Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host
J. Leukoc. Biol., November 1, 2002; 72(5): 898 - 912.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. D. Billiau, S. Fevery, O. Rutgeerts, W. Landuyt, and M. Waer
Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants
Blood, August 13, 2002; 100(5): 1894 - 1902.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Y. Mapara, Y.-M. Kim, S.-P. Wang, R. Bronson, D. H. Sachs, and M. Sykes
Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells
Blood, August 13, 2002; 100(5): 1903 - 1909.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.